Donepezil Hydrochloride
Product Images NDC 0615-7952

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 0615-7952). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Donepezilhcl.jpg (Donepezil 5mg 10mg Macleods 1)

Chemical structure diagram of Donepezil Hydrochloride, showing the molecular arrangement including methoxy groups, a piperidine ring, and a benzyl moiety with hydrochloride salt indicated.*

FDA Label Image

Fig9 (Donepezil 5mg 10mg Macleods 10)

A line graph depicting ADCS-ADL change from baseline (mean ± SE) over 6 months of drug treatment. Two groups are shown: Donepezil Hydrochloride 10 mg/day and placebo. The vertical axis measures change from baseline with clinical improvement above zero and clinical decline below. The horizontal axis shows time in months (0, 3, 6). The graph illustrates greater decline over time in the placebo group compared to the Donepezil group.*

FDA Label Image

Fig10 (Donepezil 5mg 10mg Macleods 11)

A line graph showing the cumulative percentage of patients on the y-axis versus the ADCS-ADL change from baseline on the x-axis. It compares Donepezil Hydrochloride 10 mg/day (filled circles) with placebo (open squares), illustrating patient response distribution based on changes from baseline ADCS-ADL scores.*

FDA Label Image

Donepezil 5mg Tab Bingo Card Label (Donepezil 5mg 10mg Macleods 12)

Donepezil Hydrochloride Tablets USP 5 mg packaging label. The label shows the product name and strength prominently on the top left and center. It indicates a quantity of 30 tablets with a lot number 7951 and contains multiple individual barcoded labels for Donepezil Hydrochloride Tablets USP 5 mg, each showing the lot number 7951 and manufactured or packed by Vangard Labs, Glasgow, KY 42141. Storage temperature is specified as 20°- 25°C (68°- 77°F). The label also notes "FOR INSTITUTIONAL USE ONLY" and "Mfg By Macleods (NDC 33342-027-10)".*

FDA Label Image

Donepezil 5mg Tab Unit Dose Label (Donepezil 5mg 10mg Macleods 13)

Donepezil Hydrochloride Tablet USP 5 mg labels by NCS HealthCare of KY, LLC dba Vangard Labs, Glasgow, KY. The sheet displays multiple identical labels with strength, dosage form, lot number 7951, and barcode. The lower section includes a detailed label stating Donepezil HCl Tablets USP 5 mg, quantity 30, Rx Only, storage instructions, manufacturer Macleods, repackaged by Vangard Labs, and barcodes.*

FDA Label Image

Donepezil 10mg Bingo Card Label (Donepezil 5mg 10mg Macleods 14)

Donepezil Hydrochloride Tabs USP 10 mg label for a 30-count package. The label shows the product name, strength, dosage form, and manufacturing by Macleods with packaging by Vangard Labs, Glasgow, KY. It includes barcodes, lot number 7952, and storage instructions at 20°-25°C. Marked for institutional use only with Omnicare trademark on the outer configuration.*

FDA Label Image

Donepezil 10mg Unit Dose Label (Donepezil 5mg 10mg Macleods 15)

Packaging label images for Donepezil Hydrochloride tablets, USP 10 mg, repackaged by Vangard Labs, Glasgow, KY 42141. The label includes multiple identical barcode panels for the 10 mg strength and a main label indicating Donepezil HCl Tablets USP 10 mg, quantity 30, storage instructions, and manufacturer Macleods. The label set is intended for institutional use only.*

FDA Label Image

Fig1 (Donepezil 5mg 10mg Macleods 2)

A line graph depicting ADAS-cog mean change from baseline over weeks of drug treatment for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The y-axis represents change from baseline with clinical improvement and decline indicated, and the x-axis shows weeks of treatment up to 24. Data points with error bars illustrate the trends for each group.*

FDA Label Image

Fig2 (Donepezil 5mg 10mg Macleods 3)

A cumulative percentage of patients line graph comparing Donepezil Hydrochloride 5 mg and 10 mg doses versus placebo. The x-axis shows change from baseline ranging from -15 to 15, and the y-axis shows cumulative percentage of patients from 0 to 100%. The graph includes three lines: Donepezil Hydrochloride 10 mg (circles), 5 mg (triangles), and placebo (squares). A table inset shows percentage of patients by treatment group achieving changes of -7, -4, or 0 in ADAS-cog scores.*

FDA Label Image

Fig3 (Donepezil 5mg 10mg Macleods 4)

A bar chart comparing the percentage of patients by CIBIC-plus Rating across three treatment groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo. The ratings range from Markedly Improved to Markedly Worse along the x-axis, with percentages from 0 to 50 on the y-axis. Bars show distributions of patient responses by treatment group for each rating category.*

FDA Label Image

Fig4 (Donepezil 5mg 10mg Macleods 5)

A line graph showing the mean change from baseline in ADAS-cog scores over 15 weeks of drug treatment. It compares Donepezil Hydrochloride at 5 mg/day, 10 mg/day, and placebo groups. The y-axis ranges from clinical improvement to clinical decline, with data points at 0, 3, 6, 9, 12, and 15 weeks on the x-axis.*

FDA Label Image

Fig5 (Donepezil 5mg 10mg Macleods 6)

A cumulative percentage graph comparing patient changes from baseline in ADAS-cog scores for Donepezil Hydrochloride 5 mg/day, 10 mg/day, and placebo groups. The graph displays curves for each group and includes vertical lines marking 7 points, 4 points, and no change, alongside a table summarizing treatment group percentages at specified changes.*

FDA Label Image

Fig6 (Donepezil 5mg 10mg Macleods 7)

A bar chart depicting the percentage of patients by CIBIC-plus Rating categories comparing Donepezil Hydrochloride 5 mg/day, 10 mg/day, and Placebo groups. The categories range from Markedly Improved to Markedly Worse, with data presented for each treatment group across these outcomes.*

FDA Label Image

Fig7 (Donepezil 5mg 10mg Macleods 8)

A line graph comparing SIB (Severe Impairment Battery) change from baseline mean with standard error over 6 months of drug treatment. It shows Donepezil Hydrochloride 10 mg/day versus placebo, with Donepezil demonstrating clinical improvement while placebo shows clinical decline over time.*

FDA Label Image

Fig8 (Donepezil 5mg 10mg Macleods 9)

A cumulative percentage of patients plot comparing Donepezil Hydrochloride 10 mg/day and placebo groups by SIB change from baseline. The x-axis shows SIB change from baseline, and the y-axis shows cumulative percentage of patients. The curve with filled circles represents Donepezil Hydrochloride, and the curve with open squares represents placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.